Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078909 · ClinicalTrials.gov registry record · Phase 3
Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation
A Phase 3 study, sponsored by Penn State University.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT01078909: Completed Phase 3 study, sponsored by Penn State University.
NCT01078909 is a Phase 3 study that has completed, run by Penn State University. The registered enrollment target is 125 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01078909, a Phase 3 study, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the inflammatory response to in vivo and ex vivo endotoxin challenge as measured by the production over time of several inflammatory markers.
Interventions
- BIOLOGICAL Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
What the finished NCT01078909 record still lists
NCT01078909 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 1 intervention - of which Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) is the first listed.
NCT01078909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01078909 about?
NCT01078909 is a clinical study titled "Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation". The purpose of this study is to determine the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the inflammatory response to in vivo and ex vivo endotoxin challenge as measured by the production over time of several in...
What is the current status of trial NCT01078909?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2011-10. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01078909?
The interventions under investigation include: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01078909?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01078909's enrollment target sits among peer trials
125 1605th of 2000 higher than 391 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia